The SynCardia Temporary Total Artificial Heart - Evolving Clinical Role and Future Status

Login or register to view PDF.
Abstract

The SynCardia Temporary Total Artificial Heart (TAH) is the only clinically effective, Conformité Européene (CE) registered, Food and Drug Administration (FDA) approved and Centers for Medicare and Medicaid Services (CMS) reimbursed total artificial heart system available in the world today. The TAH is a complete, robust, pulsatile, biventricular replacement system indicated for use as a bridge to transplantation in cardiac transplant candidates at risk of imminent death from non-reversible biventricular failure. The TAH offers several advantages relative to present continuous flow left ventricular assist devices (LVADs), including higher ‘quality’ flow rates, reduced afterload and preload sensitivity, reduced thrombosis and stroke rates, and freedom from device-induced bleeding. More than 900 TAHs have been implanted to date, with a bridge-to-transplant success rate >79%. The availability of the new portable Freedom® driver has significantly enhanced patient mobility and made home discharge of patients possible. With home discharge, significant experience with long-term support on the TAH is now beginning to be accumulated. Technological advances continue to be imparted to the TAH system including portable driver enhancements, remote monitoring, and next-generation TAH designs.

Support: The publication of this article was funded by SynCardia Systems, Inc.

Disclosure
Marvin J Slepian, MD, is Founder, Chairman and Chief Scientific Officer of SynCardia Systems, Inc.
Correspondence
Marvin J Slepian, MD, Sarver Heart Center, University of Arizona, 1501 North Campbell Avenue, Tucson, Arizona 85724. E: slepian@email.arizona.edu
Received date
04 January 2011
Accepted date
24 January 2011
Citation
US Cardiology - Volume 8 Issue 1;2011:8(1):39-46
Correspondence
Marvin J Slepian, MD, Sarver Heart Center, University of Arizona, 1501 North Campbell Avenue, Tucson, Arizona 85724. E: slepian@email.arizona.edu
References
  1. Heart Disease and Stroke Statistics – 2010 Update, Circulation, 2010;121:e46–215.
    Crossref | PubMed
  2. Syncardia Temporary CardioWest Total Artificial Heart (TAH-t) – P030011, FDA Approval order, Issued October 15, 2004, www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfTopic/pma/pma. cfm?num=p030011 (accessed February 17, 2011).
  3. Artificial Heart Clinical Study Approvals, www.cms.gov/MedicareApprovedFacilitie/06_artificialhearts.asp (accessed February 17, 2011).
  4. Copeland JG, Arabia FA, Tsau PH, et al., Total artificial hearts: bridge to transplantation, Cardiol Clinics, 2003;21:101–13.
    Crossref | PubMed
  5. Copeland JG, Smith RG, Arabia FA, et al., CardioWest Total Artificial Heart Investigators, Cardiac replacement with a total artificial heart as a bridge to transplantation, New Engl J Med, 2004;351(9):859–67.
    Crossref | PubMed
  6. Miller LW, Pagani FD, Russell SD, et al., for the HeartMate II Clinical Investigators, Use of a continuous-flow device in pateints awaiting heart transplantation, N Engl J Med, 2007;357:885–96.
    Crossref | PubMed
  7. Ku DN, Blood flow in arteries, Ann Rev Fluid Mech, 1997;29:399–434.
    Crossref
  8. Younis BA, Berger SA, A turbulence model for pulsatile arterial blood flows, J Biomech Eng, 2004;126:578–84.
    Crossref | PubMed
  9. Loebe M, Koster A, Sänger S, et al., Inflammatory response after implantation of a left ventricular assist device: comparison between the axial flow MicroMed DeBakey VAD and the pulsatile Novacor Device, ASAIO Journal, 2001;47:272–4.
    Crossref | PubMed
  10. John R, Panch S, Hrabe J, et al., Activation of endothelial and coagulation systems in left ventricular assist device recipients, Ann Thoracic Surg, 2009;88:1171–9.
    Crossref | PubMed
  11. Nakano T, Tominaga R, Morita S, et al., Impacts of pulsatile systemic circulation on endothelium-derived nitric oxide release in anesthetized dogs, Ann Thorac Surg, 2001;72:156–62.
    Crossref | PubMed
  12. Uriel N, Pak SW, Jorde UP, et al., Acquired von Willebrand syndrome after continuous-flow mechanical device support contributes to a high prevalence of bleeding during long-term support and at the time of transplantation, J Am Coll Cardiol, 2010;56:1207–13.
    Crossref | PubMed
  13. Heilmann C, Geisen U, Beyersdorf F, et al., Acquired von Willebrand syndrome in patients with ventricular assist device or total artificial heart, Thromb Haemost, 2010;103(5):962–7.
    Crossref | PubMed
  14. Cowger J, Pagani FD, Haft JW, et al., The development of aortic insufficiency in left ventricular assist device-supported patients, Circ Heart Fail, 2010;3:668–74.
    Crossref | PubMed
  15. Di Bella I, Pagani F, Banfi C, et al., Results with the Novacor Assist System and evaluation of long-term assistance, European J Cardio Thoracic Surg, 2000;18:112–6.
    Crossref | PubMed
  16. Frazier OH, Rose EA, Oz MC, et al., for the HeartMate LVAS Investigators, Multi-center clinical evaluation of the Heartmate vented electric left ventricular assist system in patients awaiting heart transplantation, J Thorac Cardiovasc Surg, 2001;122:1186–95.
    Crossref | PubMed
  17. Slaughter MS, Rogers JG, Milano CA, et al., for the HeartMate II Investigators, Advanced heart failure treated with continuousflow left ventricular assist device, N Engl J Med, 2009;361:2241–51.
    Crossref | PubMed
  18. Copeland JG, Smith RG, Arabia FA, et al., Total artificial heart bridge to transplantation: a 9-year experience with 62 patients, J Heart Lung Transplant, 2004;23:823–31.
    Crossref | PubMed
  19. Leprince P, Bonnet N, Rama A, et al., Bridge to transplantation with the Jarvik-7 (CardioWest) total artificial heart: a single center 15-year experience, J Heart Lung Transplant, 2003;22:1296–303.
    Crossref | PubMed
  20. 2001 Annual report of the U.S. Organ Procurement and Transplantation Network and the scientific Registry of Transplantation Recipients, Vol. 1, Washington, DC: Department of Health and Human Services, 2001:439–83.
  21. INTERMACS Quarterly Statistical Report, #HHSN268200548198C, issued 7/23/2010. Available at: www.uab.edu/ctsresearch/intermacs/statisticalsummaries.htm (accessed February 17, 2011).
  22. Intermacs Selected PowerPoint Slides, issued 3/31/09, www.uab.edu/ctsresearch/intermacs/statisticalsummaries.htm (accessed February 17, 2011).
  23. Syncardia Total Artificial Heart – Indication for use, www.fda.gov/ohrms/dockets/ac/04/briefing/4029b1_final.pdf (accessed February 17, 2011).
  24. Slepian MJ, Copeland JC, The Total Artificial Heart in refractory cardiogenic shock: saving the patient versus saving the heart, Nat Clin Prac Cardiovasc Med, 2008;5:64–5.
    Crossref | PubMed
  25. Leprince P, Bonnet N, Varnous S, et al., Patients with a body surface area less than 1.7m2 have a good outcome with the CardioWest Total Artificial Heart, J Heart Lung Transplant, 2005;24:1501–5.
    Crossref | PubMed
  26. Dang NC, Topkara VK, Mercando M, et al., Right heart failure after left ventricular assist device implantation in patients with chronic congestive heart failure, J Heart Lung Transplant, 2006;25:1–6.
    Crossref | PubMed
  27. Oz MC, Goldstein DJ, Pepino P, et al., Screening scale predicts patients successfully receiving long-term implantable left ventricular assist devices, Circulation, 1995;92:169–73.
    Crossref | PubMed
  28. Farrar DJ, Preoperative predictors of survival in patients with Thoratec ventricular assist devices as a bridge to heart transplantation. Thoratec Ventricular Assist Device Principal Investigators, J Heart Lung Transplant, 1994;13:93–101.
    PubMed
  29. Copeland JG, Smith RG, Bose RK, et al., Risk factor analysis for bridge to transplantation with the CardioWest total artificial heart, Ann Thorac Surg, 2008;85:1639–44.
    Crossref | PubMed
  30. Leshnower BG, Smith RG, OHara ML, et al., Is the Total Artificial Heart Superior to BIVAD Therapy as a Method of Bridging Patients to Heart Transplantation? 43rd Annual meeting of the Society of Thoracic Surgeons, San Diego, CA, January 2007.
  31. Roger VL, The heart failure epidemic, Int J Environ Res Public Health, 2010;7:1807–30.
    Crossref | PubMed